According to
Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best diagnostic & research stocks to buy right now are:
1. Qiagen Nv (NYSE:QGEN)
Qiagen Nv (NYSE:QGEN) is the #1 top diagnostic & research stock out of 58 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year.
Learn more.
The Component Grade breakdown for Qiagen Nv (NYSE:QGEN) is: Value: B, Growth: C, Momentum: C, Sentiment: C, Safety: C, Financials: B, and AI: C.
Qiagen Nv (NYSE:QGEN) has a Due Diligence Score of 23, which is -4 points lower than the diagnostic & research industry average of 27. Although this number is below the industry average, our proven quant model rates QGEN as a "A".
QGEN passed 9 out of 38 due diligence checks and has weak fundamentals. Qiagen Nv has seen its stock lose -1.42% over the past year, overperforming other diagnostic & research stocks by 24 percentage points.
Qiagen Nv has an average 1 year
price target of $48.25, an upside of 14.34% from Qiagen Nv's current stock price of $42.20.
Qiagen Nv stock has a consensus Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Qiagen Nv, 25% have issued a Strong Buy rating, 0% have issued a Buy, 75% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.
2. Illumina (NASDAQ:ILMN)
Illumina (NASDAQ:ILMN) is the #2 top diagnostic & research stock out of 58 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year.
Learn more.
The Component Grade breakdown for Illumina (NASDAQ:ILMN) is: Value: B, Growth: A, Momentum: F, Sentiment: C, Safety: B, Financials: B, and AI: C.
Illumina (NASDAQ:ILMN) has a Due Diligence Score of 16, which is -11 points lower than the diagnostic & research industry average of 27. Although this number is below the industry average, our proven quant model rates ILMN as a "B".
ILMN passed 5 out of 33 due diligence checks and has weak fundamentals. Illumina has seen its stock lose -38.63% over the past year, underperforming other diagnostic & research stocks by -13 percentage points.
Illumina has an average 1 year
price target of $129.17, an upside of 68.82% from Illumina's current stock price of $76.51.
Illumina stock has a consensus Buy recommendation according to Wall Street analysts. Of the 12 analysts covering Illumina, 33.33% have issued a Strong Buy rating, 8.33% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 8.33% have issued a Strong Sell.
3. Agilent Technologies (NYSE:A)
The Component Grade breakdown for Agilent Technologies (NYSE:A) is: Value: B, Growth: C, Momentum: D, Sentiment: C, Safety: A, Financials: B, and AI: B.
Agilent Technologies (NYSE:A) has a Due Diligence Score of 47, which is 20 points higher than the diagnostic & research industry average of 27.
A passed 17 out of 38 due diligence checks and has strong fundamentals. Agilent Technologies has seen its stock lose -23.24% over the past year, overperforming other diagnostic & research stocks by 2 percentage points.
Agilent Technologies has an average 1 year
price target of $141.86, an upside of 33.25% from Agilent Technologies's current stock price of $106.46.
Agilent Technologies stock has a consensus Buy recommendation according to Wall Street analysts. Of the 7 analysts covering Agilent Technologies, 14.29% have issued a Strong Buy rating, 14.29% have issued a Buy, 71.43% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.
